Long-term efavirenz use is associated with worse neurocognitive functioning in HIV-infected patients

Journal of NeuroVirology

Volumn 22, Issue 2, 2016, Pages 170-178

  Ma, Qing ^a,g   Vaida, Florin ^a   Wong, Jenna ^a   Sanders, Chelsea A ^a   Kao, Yu ting ^a   Croteau, David ^a   Clifford, David B ^b   Collier, Ann C ^c   Gelman, Benjamin B ^d   Marra, Christina M ^c   McArthur, Justin C ^e   Morgello, Susan ^f   Simpson, David M ^f   Heaton, Robert K ^a   Grant, Igor ^a   Letendre, Scott L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

Author keywords

Efavirenz; Hepatitis C virus coinfection; Long term antiretroviral therapy; Lopinavir ritonavir; Neurocognitive function; Neurotoxicity

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; LOPINAVIR; RITONAVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; COGNITION ASSESSMENT; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NEUROLOGICAL COMPLICATION; NEUROTOXICITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT DURATION; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COGNITIVE DYSFUNCTION; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; EXECUTIVE FUNCTION; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOLOGY; LEARNING; MEMORY; MIDDLE AGED; MIXED INFECTION; NEUROPSYCHOLOGICAL TEST; PATHOPHYSIOLOGY; PHYSIOLOGY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COGNITIVE DYSFUNCTION; COINFECTION; DRUG THERAPY, COMBINATION; EXECUTIVE FUNCTION; FEMALE; HEPACIVIRUS; HEPATITIS C; HIV INFECTIONS; HIV-1; HUMANS; LOPINAVIR; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RITONAVIR; VERBAL LEARNING;

EID: 84960809030     PISSN: 13550284     EISSN: 15382443     Source Type: Journal    
DOI: 10.1007/s13365-015-0382-7     Document Type: Article

References (38)

1. Antinori A, Arendt G, Becker JT et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799
2. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. World Health Organization. Geneva, Switzerland 2006
3. Beck AT, Steer RA, Brown GK (1996) Manual for the beck depression inventory-II. Psychological Corporation, San Antonio
4. Best BM, Koopmans PP, Letendre SL et al (2011) Efavirenz concentrations in CSF exceed IC50 for wild-type HIV. J Antimicrob Chemother 66(2):354–357
5. Brandmann M, Nehls U, Dringen R (2013) 8-Hydroxy-efavirenz, the primary metabolite of the antiretroviral drug Efavirenz, stimulates the glycolytic flux in cultured rat astrocytes. Neurochem Res 38(12):2524–2534
6. Brown LA, Jin J, Ferrell D et al (2014) Efavirenz promotes beta-secretase expression and increased Abeta1-40,42 via oxidative stress and reduced microglial phagocytosis: implications for HIV associated neurocognitive disorders (HAND). PLoS One 9(4):e95500
7. Bunupuradah T, Chetchotisakd P, Jirajariyavej S et al (2012) Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy. J Neurovirol 18(6):479–487
8. Capparelli EV, Holland D, Okamoto C et al (2005) Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV. AIDS 19(9):949–952
9. Carey CL, Woods SP, Gonzalez R et al (2004) Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol 26(3):307–319
10. Cherner M, Letendre S, Heaton RK et al (2005) Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 64(8):1343–1347
11. Ciccarelli N, Fabbiani M, Di Giambenedetto S et al (2011) Efavirenz associated with cognitive disorders in otherwise asymptomatic HIV-infected patients. Neurology 76(16):1403–1409
12. Clifford DB, Evans S, Yang Y et al (2005) Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med 143(10):714–721
13. Clifford DB, Evans S, Yang Y, Acosta EP, Ribaudo H, Gulick RM (2009) Long-term impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals (ACTG 5097s). HIV Clin Trials 10(6):343–355
14. Ellis R, Langford D, Masliah E (2007) HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci 8(1):33–44
15. Fletcher NF, Wilson GK, Murray J et al (2012) Hepatitis C virus infects the endothelial cells of the blood–brain barrier. Gastroenterology 142(3):634–643, e6
16. Garvey LJ, Pavese N, Ramlackhansingh A et al (2012) Acute HCV/HIV coinfection is associated with cognitive dysfunction and cerebral metabolite disturbance, but not increased microglial cell activation. PLoS One 7(7):e38980
17. Gutierrez F, Navarro A, Padilla S et al (2005) Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41(11):1648–1653
18. Heaton RK, Clifford DB, Franklin DR Jr et al (2010) HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 75(23):2087–2096
19. Ikezu T (2009) The aging of human-immunodeficiency-virus-associated neurocognitive disorders. J NeuroImmune Pharm 4(2):161–162
20. Justice AC, McGinnis KA, Atkinson JH et al (2004) Psychiatric and neurocognitive disorders among HIV-positive and negative veterans in care: veterans aging cohort five-site study. AIDS 18(Suppl 1):S49–S59
21. Kanmogne GD, Kuate CT, Cysique LA et al (2010) HIV-associated neurocognitive disorders in sub-Saharan Africa: a pilot study in Cameroon. BMC Neurol 10:60
22. Kaul M, Garden GA, Lipton SA (2001) Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 410(6831):988–994
23. Letendre S (2011) Central nervous system complications in HIV disease: HIV-associated neurocognitive disorder. Top Antivir Med 19(4):137–142
24. Letendre SL, Cherner M, Ellis RJ et al (2005) The effects of hepatitis C, HIV, and methamphetamine dependence on neuropsychological performance: biological correlates of disease. AIDS 19(Suppl 3):S72–S78
25. Letendre S, Croteau D, Ellis Ret al. Lower CSAR are associated with global neurocognitive impairment in antiretroviral-treated people with HIV. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, 2011: Abstract 408
26. Marquine MJ, Umlauf A, Rooney AS et al (2014) The veterans aging cohort study index is associated with concurrent risk for neurocognitive impairment. J Acquir Immune Defic Syndr 65(2):190–197
27. Morgan EE, Woods SP, Rooney A, Perry W, Grant I, Letendre SL (2012) Intra-individual variability across neurocognitive domains in chronic hepatitis C infection: elevated dispersion is associated with serostatus and unemployment risk. Clin Neuropsychol 26(4):654–674
28. Robertson K, Liner J, Meeker RB (2012a) Antiretroviral neurotoxicity. J Neurovirol 18(5):388–399
29. Robertson K, Jiang H, Kumwenda J et al (2012b) Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis 55(6):868–876
30. Sacktor N, Nakasujja N, Skolasky R et al (2006) Antiretroviral therapy improves cognitive impairment in HIV+ individuals in sub-Saharan Africa. Neurology 67(2):311–314
31. Santos JR, Munoz-Moreno JA, Molto J et al (2013) Virological efficacy in cerebrospinal fluid and neurocognitive status in patients with long-term monotherapy based on lopinavir/ritonavir: an exploratory study. PLoS One 8(7):e70201
32. Thiyagarajan A, Garvey LJ, Pflugrad H et al (2010) Cerebral function tests reveal differences in HIV-infected subjects with and without chronic HCV co-infection. Clin Microbiol Infect 16(10):1579–1584
33. Tovar-y-Romo LB, Bumpus NN, Pomerantz D et al (2012) Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 343(3):696–703
34. Valcour V, Paul R, Chiao S, Wendelken LA, Miller B (2011) Screening for cognitive impairment in human immunodeficiency virus. Clin Infect Dis 53(8):836–842
35. Vivithanaporn P, Nelles K, DeBlock L, Newman SC, Gill MJ, Power C (2012) Hepatitis C virus co-infection increases neurocognitive impairment severity and risk of death in treated HIV/AIDS. J Neurol Sci 312(1–2):45–51
36. Winston A, Garvey L, Scotney E et al (2010) Does acute hepatitis C infection affect the central nervous system in HIV-1 infected individuals? J Viral Hepat 17(6):419–426
37. Winston A, Garvey L, Sabin CA (2011) Superior neurocognitive function is associated with central nervous system antiretroviral drug penetration only in regimens containing more than three antiretroviral agents. AIDS 25(7):1014–1015
38. Winston A, Puls R, Kerr SJ et al (2012) Dynamics of cognitive change in HIV-infected individuals commencing three different initial antiretroviral regimens: a randomized, controlled study. HIV Med 13(4):245–251